Clinical trial
A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy…
NCT00214214 · University of Wisconsin, Madison, Other · Withdrawn
Key facts
| NCT number | NCT00214214 |
|---|---|
| Title | A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus |
| Official title | A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | New Onset Type 1 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Campath 1H® (Alemtuzumab) |
| Enrollment | 0 |
| Start date | Oct 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Oct 8, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: